1L (PRIMA): Median PFS i ITT kohort (både BRCAmut og BRCAwt pasienter) ZEJULA vs. placebo: 13,8 vs 8,2 mnd, HR: 0,62 (95% KI: 0,50–0,76; p<0,001)2
Median PFS i HRd kohorten: ZEJULA vs. placebo: 21,9 vs 10,4 mnd, HR: 0.43 (95% KI: 0,31–0,59; p<0,001)2
2L (NOVA): Median PFS i gBRCAmut kohort ZEJULA vs. placebo: 21,0 vs 5,5 mnd, HR: 0,27 (95% KI: 0,17–0,41; p<0.0001)3
Median PFS i ikke-gBRCAmut kohorten: ZEJULA vs. placebo: 9,3 vs 3,9 mnd, HR: 0.45 (95% KI: 0,34–0,61; p<0.0001)3
- Zejula preparatomtale
- Gonzalez Martin A, Pothuri B, Vergote I et al. N Engl J Med 2019;381(25):2391-2402.
- Mirza MR, Monk BJ, Herrstedt J et al. N Engl J Med 2016; 375(22):2154-64
- LIS anbefalinger for Onkologiske og kolonistimulerende legemidler
Zejula trademark is a registered trademark of the GSK group of companies.
© 2021 GSK group of companies or its licensor..